Kala pharmaceuticals, inc. (KALA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Product revenues, net

1,071

1,180

1,451

2,057

1,386

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Cost of product revenues

354

747

668

352

241

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

15,408

14,492

15,280

17,007

18,236

14,329

8,469

7,151

5,482

-

-

-

-

-

-

Research and development

5,434

6,138

7,070

7,108

6,959

9,238

7,027

7,368

5,657

5,880

7,018

8,071

8,039

8,256

5,950

General and administrative

-

-

-

-

-

-

-

-

-

-

2,516

1,559

1,532

1,491

3,700

Total costs and expenses

21,196

21,377

23,018

24,467

25,436

23,567

15,496

14,519

11,139

11,140

9,534

9,630

9,571

9,747

9,650

Loss from operations

-20,125

-20,197

-21,567

-22,410

-24,050

-23,567

-15,496

-14,519

-11,139

-11,140

-9,534

-9,630

-9,571

-9,747

-9,650

Other income (expense):
Interest income

298

384

571

646

756

840

325

313

209

250

194

37

46

60

30

Interest expense

2,128

2,145

2,180

2,061

2,094

2,101

432

414

367

401

212

208

198

186

186

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

0

623

1,185

36

-206

47

Total other expense

-1,830

-1,761

-1,609

-1,415

-1,338

-1,651

-107

-101

-158

-151

-641

-1,356

-188

80

-203

Net loss

-21,955

-21,958

-23,176

-23,825

-25,388

-25,218

-15,603

-14,620

-11,297

-11,291

-10,175

-10,986

-9,759

-9,667

-9,853

Net loss per share—basic and diluted

-0.54

-0.63

-0.68

-0.70

-0.75

-0.80

-0.63

-0.60

-0.46

14.41

-0.56

-9.30

-8.26

-8.18

-8.34

Weighted average shares outstanding—basic and diluted

40,761

34,909

34,168

33,882

33,878

33,306

24,600

24,567

24,542

25,102

18,034

1,181

1,181

1,181

1,181